Continuation rates with a levonorgestrel-releasing contraceptive implant (Norplant®) -: A prospective study in Belgium

被引:23
作者
Vekemans, M
Delvigne, A
Paesmans, M
机构
[1] CHU St Pierre, Dept Gynaecol Obstet, Family Planning Clin, B-1000 Brussels, Belgium
[2] Free Univ Brussels, Inst Bordet, Biostat Unit, Brussels, Belgium
关键词
contraception; levonorgestrel; Norplant (R) implants; continuation rates; Belgium;
D O I
10.1016/S0010-7824(97)00155-8
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Contraceptive protection offered by a method depends on its duration of use, which reflects costs, side effects, and relatives' opinions. This study investigated in Norplant((R)) implants users the continuation rates, some of their determinants, and the motives for removals. Since 1988, 612 Norplant implants sets, designed to protect for 5 years, have been inserted. Observing 13,907 months of use, we determined over time the continuation rates and how age, parity, circumstances at insertion (postpartum, postabortum, others), and patronymic origins (surrogate for sociocultural factors) influenced them. Statistics included Kaplan-Meier's method and log rank tests, and uni-and multivariate Cox models. Continuation increased with age and depended on sociocultural factors. Parity exerted influence only in younger women. Median duration of use was 3 years 11 months. Removals before 5 years related almost equally to irregular bleeding, other side effects, and pregnancy wish. The cumulative 5-year failure rate was 1.5%. Unsatisfied users returned earlier, distorting the first results. A literature search showed that implants yield, in the mean, slightly better continuation figures than do intrauterine devices, and clearly higher than those obtained with pills and injectables. To optimize costs and counseling, warnings about the risk of short duration of use in young nullipara, especially if negative sociocultural influences prevail, are recommended. In no category are the implants absolutely to be avoided. Individual and programmatic contraceptive choice should take into account the expected continuation of use. (C) 1997 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:291 / 299
页数:9
相关论文
共 41 条
[1]   5-YEAR EXPERIENCE WITH NORPLANT [J].
AFFANDI, B ;
SANTOSO, SSI ;
DJAJADILAGA ;
HADISAPUTRA, W ;
MOELOEK, FA ;
PRIHARTONO, J ;
LUBIS, F ;
SAMIL, RS .
CONTRACEPTION, 1987, 36 (04) :417-428
[2]  
AGUILLAUME CJ, 1994, REF GYN OBSTETR, V2, P268
[3]   THE USE OF NORPLANT AND DEPO-PROVERA IN ADOLESCENTS [J].
AMMERMAN, SD .
JOURNAL OF ADOLESCENT HEALTH, 1995, 16 (05) :343-346
[4]  
ARCHER DF, 1995, CONTEMP OBSTET GYNEC, V40, P11
[5]   USE OF LEVONORGESTREL IMPLANTS VERSUS ORAL-CONTRACEPTIVES IN ADOLESCENCE - A CASE-CONTROL STUDY [J].
BERENSON, AB ;
WIEMANN, CM .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1995, 172 (04) :1128-1137
[6]  
BISWAS A, 1995, BRIT J FAM PLAN, V21, P11
[7]  
BLAIN S, 1995, BRIT J FAM PLAN, V21, P17
[8]   A REVIEW OF SAFETY, EFFICACY, PROS AND CONS, AND ISSUES OF PUERPERAL TUBAL-STERILIZATION - AN UPDATE [J].
CHI, IC ;
PETTA, CA ;
MCPHEETERS, M .
ADVANCES IN CONTRACEPTION, 1995, 11 (03) :187-206
[9]   Effectiveness of Norplant(R) implants among Thai women in Bangkok [J].
Chompootaweep, S ;
Kochagarn, E ;
Sirisumpan, S ;
Tangusaha, J ;
Theppitaksak, B ;
Dusitsin, N .
CONTRACEPTION, 1996, 53 (01) :33-36
[10]   A PRELIMINARY-REPORT OF NORPLANT(R) IMPLANT INSERTIONS IN A LARGE URBAN FAMILY-PLANNING PROGRAM [J].
CROSBY, UD ;
SCHWARZ, BE ;
GLUCK, KL ;
HEARTWELL, SF .
CONTRACEPTION, 1993, 48 (04) :359-366